Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LDHA | P00338 | 1/20 | 0.37 |
| ▸ | EEF2K | O00418 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.31 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL444311 | 0.86 | LDHA (0.36) | LDHALMNAPARP1HTTPARP2 | |
| SCHEMBL28639430 | 0.83 | CNR2 (0.36) | LDHALMNAPARP1HTTPARP2 | |
| Caricotamide SCHEMBL6546956 | 0.82 | LDHA (0.37) | LDHA | |
| SCHEMBL2205423 | 0.76 | ADRA1D (0.41) | PARP1 | |
| SCHEMBL23010949 | 0.76 | LDHA (0.34) | LDHA | |
| SCHEMBL1274356 | 0.76 | LDHA (0.36) | LDHAPARP1 | |
| SCHEMBL20815978 | 0.74 | GSK3A (0.42) | PARP1HTTPARP2PARP10 | |
| SCHEMBL9334115 | 0.73 | LDHA (0.33) | LDHA | |
| SCHEMBL14473419 | 0.73 | LDHA (0.33) | LDHA | |
| SCHEMBL20829870 | 0.71 | LDHA (0.34) | LDHA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3901160-A1 | NICOTINAMIDE MONONUCLEOTIDE AND NICOTINAMIDE RIBOSIDE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF VIRAL INFECTIONS AND RESPIRATORY COMPLICATIONS, IN PARTICULAR CAUSED BY INFLUENZAVIRUS OR CORONAVIRUS | Nuvamid SA (CH) | 2021-10-27 | — | — | EP | disclosed |
| US-7968013-B2 | Carbon nanotube N-doping material, carbon nanotube N-doping method and device using the same | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2011-06-28 | — | — | US | disclosed |
| US-20100140561-A1 | CARBON NANOTUBE N-DOPING MATERIAL, CARBON NANOTUBE N-DOPING METHOD AND DEVICE USING THE SAME | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100140561-A1 | CARBON NANOTUBE N-DOPING MATERIAL, CARBON NANOTUBE N-DOPING METHOD AND DEVICE USING THE SAME | NNMT, NNT, NAMPT | LDHA 537/4885EEF2K 4640/4885LMNA 732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.